Human metapneumovirus (HMPV) is a common respiratory virus that causes cold‑ or flu‑like illness, but it can sometimes lead to serious lung infections in babies, older adults, and people with weak immune systems. There is currently no specific antiviral treatment or approved vaccine for HMPV, so prevention and symptom management are the main strategies.
What Is HMPV?
Human metapneumovirus is a respiratory virus in the Pneumoviridae family, the same family as respiratory syncytial virus (RSV).[] HMPV was first identified in 2001 but has likely been circulating in humans for many decades.
According to the Centers for Disease Control and Prevention (CDC), HMPV can infect people of all ages and is a well‑recognized cause of respiratory illness worldwide. The World Health Organization (WHO) notes that HMPV usually causes mild, cold‑like symptoms, but in some cases it can trigger serious lower respiratory tract infections such as bronchiolitis or pneumonia.
Several recent reviews, including a 2025 paper in Emerging Infectious Diseases and a 2025 overview in PMC, highlight that Human metapneumovirus is now considered one of the major viral drivers of acute respiratory infections globally, alongside influenza and RSV.
HMPV Symptoms: Mild to Severe
Common symptoms
In most healthy people, Human metapneumovirus looks and feels like a typical cold or mild flu. The CDC and WHO list the most common symptoms as:
- Cough
- Fever
- Runny or stuffy nose
- Sore throat
- Nasal congestion
- Shortness of breath (especially in more severe cases)
- Headache and body aches
- Fatigue or general tiredness
Clinical summaries from Cleveland Clinic and educational resources like Primary Care 24 note that wheezing can also occur, particularly in people with asthma or other lung problems.
The WHO Q&A on hMPV emphasises that symptom severity varies widely depending on your overall health, age and any underlying medical conditions.
When illness becomes more serious
While severe illness is less common, Human metapneumovirus can cause or worsen lower respiratory tract infections, especially in vulnerable groups. Complications described by the CDC, WHO and hospital‑based reviews include:
- Bronchitis and bronchiolitis (infection of the bronchial tubes and small airways)
- Pneumonia
- Asthma attacks or reactive airway disease flares
- Croup in young children (barking cough, noisy breathing)
- Middle ear infections in children
Signs that an HMPV infection may be becoming serious include: difficulty breathing, fast or laboured breathing, chest pain, persistent high fever, blue lips or face, confusion, or signs of dehydration. The CDC advises seeking urgent medical care if these red‑flag symptoms appear.
A clinical guide from the Alabama Regional Center for Infection Prevention and Control summarises it simply: most cases are mild, but HMPV poses greater risk to infants, older adults and people with weakened immune systems.
How HMPV Spreads
HMPV spreads in much the same way as other respiratory viruses like RSV and the common cold. Public‑health agencies describe three main routes:
- Respiratory droplets in the air – when an infected person coughs, sneezes, or talks at close range
- Close personal contact – such as hugging, caring for someone, or shaking hands
- Touching contaminated surfaces – then touching your mouth, nose, or eyes
The Chinese Center for Disease Control and Prevention explains that HMPV is mainly transmitted via droplets and aerosols, and that close contact in crowded environments (schools, workplaces, public transport) increases risk. The China CDC information page on HMPV also notes that poor hand hygiene and exposure to contaminated environments facilitate spread.
According to the CDC, infections can occur any time of year, but in many countries HMPV has a clear seasonal pattern, with most cases occurring from late winter through spring. A 2025 meta‑analysis in PMC shows that in temperate regions, HMPV typically peaks in winter‑spring and can co‑circulate with influenza and RSV. The WHO’s January 2025 advisory on acute respiratory infections similarly highlights increased activity of HMPV during the Northern Hemisphere winter.
Who Is Most at Risk?
Anyone can get HMPV, and most people are infected for the first time during early childhood. However, certain groups are more likely to develop severe illness or require hospital care.
High‑risk groups include:
- Infants and young children, especially under 5 years
- Older adults, particularly over 65
- People with chronic lung disease (asthma, COPD)
- People with heart disease
- Those with weakened immune systems, including cancer patients, transplant recipients and those on immune‑suppressing medications
A study in Emerging Infectious Diseases estimated that HMPV causes 5–25% of respiratory infections among infants and children and up to about 10% among adults. It also accounts for a significant fraction of hospitalisations for lower respiratory illness in children.
The Gavi “VaccinesWork” explainer on HMPV points out that, although HMPV is not currently considered to have strong “pandemic potential,” it still causes a substantial burden of disease in vulnerable groups and should be taken seriously. WHO’s 2025 Q&A likewise underscores its role as an “important cause of respiratory infection globally.”
HMPV vs. COVID‑19, RSV and Flu
Because HMPV causes generic “cold and flu‑like” symptoms, it often gets confused with other respiratory infections. Understanding the differences helps clinicians decide when to test and how to manage risk.
Resources from Primary Care 24 and several 2025 reviews summarise the distinctions:
- HMPV vs RSV: Both belong to the same virus family and can cause wheezing, bronchiolitis and pneumonia in children. RSV tends to cause more severe disease in very young infants and is historically a more common cause of hospitalisation, but HMPV’s impact is now recognised as comparable in some settings.
- HMPV vs influenza (flu): Influenza often produces more intense systemic symptoms like high fever, pronounced muscle aches and extreme fatigue, and is associated with sharp, well‑defined seasonal outbreaks. HMPV symptoms can be slightly milder but still overlap; lab testing is usually required to distinguish them.
- HMPV vs COVID‑19: Both can cause cough, fever, and shortness of breath, and both spread via respiratory droplets and close contact. However, COVID‑19 is linked with a wider range of systemic symptoms (loss of taste/smell, clotting issues) and long‑term complications in some people, whereas HMPV is primarily a respiratory pathogen.
A 2025 review in PMC concluded that HMPV’s morbidity and mortality in certain hospitalised populations can be comparable to influenza and RSV, highlighting the need for better diagnostics and preventive tools.
In Australia, this kind of sustained respiratory‑virus pressure is also shaping how hospitals, clinics and policymakers think about digital transformation and AI‑enabled care pathways, as tools like predictive triage, virtual monitoring and clinical decision support start to move from pilots into mainstream use, a shift profiled in AI in Healthcare Australia 2026: Trends Changing Care Fast.
Global Trends and Recent Outbreaks
Seasonal circulation and rising recognition
As testing has expanded since the COVID‑19 pandemic, more countries are identifying HMPV in routine respiratory panels. This doesn’t necessarily mean the virus is new; it means we are finally seeing how often it shows up when people come to hospital or clinics with respiratory illness.
The WHO’s January 2025 acute respiratory infection advisory noted increased HMPV activity in the Northern Hemisphere, alongside influenza and RSV. A briefing in BBC News reported that cases in the UK had been rising steadily since late 2024, contributing to winter pressures on hospitals.
A 2024–2025 seasonal outbreak in China drew particular attention. Data cited by the Chinese CDC and summarised in this Wikipedia overview showed HMPV linked to over 6% of positive respiratory tests and more than 5% of respiratory hospitalisations at one point, outpacing some other respiratory viruses. WHO clarified that the surge was still within the expected seasonal range but stressed the importance of surveillance and preparedness.
Is HMPV a pandemic threat?
Headlines about outbreaks have led some people to worry about HMPV becoming “the next pandemic virus.” Expert organisations have tried to put this risk into context. The Gavi “VaccinesWork” article on HMPV quotes virologists who say that, while HMPV does mutate and new strains emerge, it is not currently considered to have strong pandemic potential.
The main concern is not global collapse of health systems but ongoing, significant strain on hospitals each winter and spring, particularly paediatric and geriatric wards. A 2025 scientific review in PMC argues that enhanced surveillance, better diagnostics and eventually targeted antivirals or vaccines are needed to manage this burden effectively.
Diagnosis and Testing
Because HMPV symptoms resemble many other respiratory infections, clinicians usually cannot diagnose it based on symptoms alone. Laboratory testing is required to confirm HMPV.
The CDC explains that healthcare providers may order a respiratory panel (often a PCR test) that checks for multiple viruses at once, including HMPV, RSV, influenza, and SARS‑CoV‑2. Samples are typically taken from the nose or throat using a swab.
In routine outpatient cases with mild symptoms, many doctors will not test specifically for HMPV, since management is similar to other mild viral respiratory infections. Testing is more common in:
- Hospitalised patients with severe respiratory illness
- Infants, older adults or immunocompromised patients
- Outbreak investigations in hospitals, nursing homes or schools
The Cleveland Clinic overview notes that confirming HMPV can help clinicians rule out bacterial causes and avoid unnecessary antibiotics, which do not work against viruses.
Treatment: How Is HMPV Managed?
There is currently no specific antiviral medication approved for HMPV infection, and no licensed vaccine is available. Management is supportive, meaning it focuses on relieving symptoms and supporting breathing and hydration while the body fights the virus.
For mild cases at home, public‑health and clinical guides recommend:
- Rest and adequate fluids
- Over‑the‑counter pain relievers and fever reducers (such as paracetamol or ibuprofen), following dosing instructions
- Saline nasal sprays or rinses to ease congestion
- Humidified air to reduce coughing and soothe airways
For people with asthma, COPD or other chronic lung disease, ensuring that inhalers and action plans are up to date is important.
Serious cases, especially in high‑risk patients, may require hospital care with:
- Supplemental oxygen
- Intravenous fluids
- Respiratory support (such as non‑invasive ventilation or, rarely, mechanical ventilation)
The CDC and WHO both stress that antibiotics do not treat viruses like HMPV and should only be used if there is clear evidence of a bacterial co‑infection.
Research is ongoing to develop antiviral therapies and vaccines, as highlighted in the 2025 PMC review and other scientific articles on emerging strategies for HMPV control.
Prevention: How to Protect Yourself and Others
Because there is no vaccine yet, prevention relies on the same basic measures used for other respiratory viruses.
Everyday preventive steps
Public‑health guidance from the CDC, WHO, and national health services recommends:
- Wash hands frequently with soap and water for at least 20 seconds, or use an alcohol‑based hand sanitiser.
- Avoid close contact with people who are sick; keep some distance if someone is coughing or sneezing.
- Cover coughs and sneezes with a tissue or your elbow, then dispose of tissues and clean your hands.
- Avoid touching your eyes, nose and mouth with unwashed hands.
- Clean and disinfect frequently touched surfaces, such as doorknobs, phones and toys.
The China CDC information sheet underscores the importance of avoiding crowded settings and maintaining good ventilation, particularly during peak seasons.
If you are sick
If you suspect you have HMPV or another respiratory virus, simple actions can reduce the risk of spreading it:
- Stay home and rest until your symptoms are clearly improving.
- Wear a mask if you must be around others, especially indoors or in healthcare settings.
- Keep away from high‑risk people (babies, older relatives, immunocompromised friends) while you are unwell.
Primary‑care guidance from the UK, such as this overview from Primary Care 24, emphasises staying home when symptomatic and masking if you need to go out, mirroring COVID‑era practices that also help limit HMPV spread.
When to See a Doctor
Most HMPV infections can be managed at home, but you should seek medical advice if you:
- Have symptoms lasting longer than about a week without improvement
- Develop a high or persistent fever
- Experience worsening cough, chest pain, or difficulty breathing
- Are in a high‑risk group (young child, older adult, pregnant, immunocompromised, or have chronic heart/lung disease)
Immediate emergency care is needed if someone has severe breathing difficulty, blue lips or face, confusion, or is difficult to wake.
The Cleveland Clinic guide and UAB ARCIPC article both encourage people in higher‑risk categories to seek prompt assessment if symptoms escalate, since early supportive care can prevent complications.
Key Takeaways and Resources
HMPV is a widespread respiratory virus that most often causes mild, cold‑like illness but can sometimes lead to serious lung infections, particularly in young children, older adults and people with underlying health conditions. It spreads through respiratory droplets, close contact and contaminated surfaces, and tends to circulate in winter and spring in many regions.
There is no specific treatment or vaccine yet, so the best protection involves everyday hygiene, staying home when sick, and seeking medical care promptly if symptoms become severe. Growing surveillance data and research suggest that HMPV deserves similar attention to influenza and RSV in public‑health planning.
Episodes like rising HMPV activity, heavier winter hospital loads and long‑COVID backlogs are all landing in an Australian healthcare system that is already in the middle of rapid structural change. For a bigger picture of the pressures and reforms reshaping hospitals, primary care, funding and digital health, you can look at Australia Healthcare Trends 2026: What’s Changing Fast, which maps out the demographic, economic and policy forces driving that shift.